A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)
Latest Information Update: 03 May 2024
At a glance
- Drugs Sapablursen (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 02 May 2024 This trial has been discontinued in Hungary according to European Clinical Trials Database record.
- 23 Feb 2024 Planned number of patients changed from 48 to 60.
- 08 Jun 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2025.